Blanco Gonzalo, Puiggros Anna, Baliakas Panagiotis, Athanasiadou Anastasia, García-Malo MªDolores, Collado Rosa, Xochelli Aliki, Rodríguez-Rivera María, Ortega Margarita, Calasanz Mª José, Luño Elisa, Vargas MªTeresa, Grau Javier, Martínez-Laperche Carolina, Valiente Alberto, Cervera José, Anagnostopoulos Achilles, Gimeno Eva, Abella Eugènia, Stalika Evangelia, Hernández-Rivas Jesús Mª, Ortuño Francisco José, Robles Diego, Ferrer Ana, Ivars David, González Marcos, Bosch Francesc, Abrisqueta Pau, Stamatopoulos Kostas, Espinet Blanca
Laboratori de Citogenètica Molecular, Laboratori de Citologia Hematològica, Servei de Patologia, Hospital del Mar, Barcelona, Spain.
Grup de Recerca Translacional en Neoplàsies Hematològiques, Cancer Research Programme, IMIM-Hospital del Mar, Barcelona, Spain.
Oncotarget. 2016 Dec 6;7(49):80916-80924. doi: 10.18632/oncotarget.13106.
Patients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations (TP53abs; chromosome 17p deletion and/or TP53 mutation) exhibit an unfavorable clinical outcome. Chromosome 8 abnormalities, namely losses of 8p (8p-) and gains of 8q (8q+) have been suggested to aggravate the outcome of patients with TP53abs. However, the reported series were small, thus hindering definitive conclusions. To gain insight into this issue, we assessed a series of 101 CLL patients harboring TP53 disruption. The frequency of 8p- and 8q+ was 14.7% and 17.8% respectively. Both were associated with a significantly (P < 0.05) higher incidence of a complex karyotype (CK, ≥3 abnormalities) detected by chromosome banding analysis (CBA) compared to cases with normal 8p (N-8p) and 8q (N-8q), respectively. In univariate analysis for 10-year overall survival (OS), 8p- (P = 0.002), 8q+ (P = 0.012) and CK (P = 0.009) were associated with shorter OS. However, in multivariate analysis only CK (HR = 2.47, P = 0.027) maintained independent significance, being associated with a dismal outcome regardless of chromosome 8 abnormalities. In conclusion, our results highlight the association of chromosome 8 abnormalities with CK amongst CLL patients with TP53abs, while also revealing that CK can further aggravate the prognosis of this aggressive subgroup.
携带TP53异常(TP53abs;17号染色体p缺失和/或TP53突变)的慢性淋巴细胞白血病(CLL)患者临床预后不佳。有研究提示,8号染色体异常,即8p缺失(8p-)和8q增益(8q+)会使TP53abs患者的预后恶化。然而,既往报道的病例系列较小,因此难以得出确切结论。为深入了解这一问题,我们评估了101例存在TP53破坏的CLL患者。8p-和8q+的发生率分别为14.7%和17.8%。与8p正常(N-8p)和8q正常(N-8q)的病例相比,这两种情况均与染色体显带分析(CBA)检测到的复杂核型(CK,≥3种异常)的发生率显著更高(P<0.05)相关。在对10年总生存期(OS)的单变量分析中,8p-(P=0.002)、8q+(P=0.012)和CK(P=0.009)与较短的OS相关。然而,在多变量分析中,只有CK(HR=2.47,P=0.027)保持独立显著性,无论8号染色体是否异常,均与不良预后相关。总之,我们的结果突出了8号染色体异常与TP53abs的CLL患者中CK的关联,同时也揭示了CK可进一步恶化这一侵袭性亚组的预后。